McKesson Director Lynne Doughtie Receives Restricted Stock Unit Grant Worth 277 Shares

McKesson's Annual Director Equity Compensation Program

McKesson Corporation, a leading healthcare logistics and technology company headquartered in Irving, Texas, provides supply chain solutions, healthcare IT platforms, and specialty pharmaceutical services to hospitals, pharmacies, and healthcare providers across North America. The company distributes pharmaceuticals, medical supplies, and healthcare information technology solutions that serve more than 100,000 locations worldwide.

The restricted stock unit grant disclosed in this report represents part of McKesson's annual director compensation structure. Director compensation at large publicly traded companies typically combines cash retainers, meeting fees, and equity awards designed to align board members' interests with shareholder value creation. The 2022 Stock Plan, under which this grant was made, is McKesson's equity incentive program that governs stock awards and options for employees, executives, and directors.

Details of the Restricted Stock Unit Grant

Lynne M. Doughtie, identified in the disclosure as a director of McKesson, received 277 restricted stock units on July 22, 2026. The units were granted at a deemed price of $0, which is standard for restricted stock unit awards issued as compensation rather than through a purchase transaction. This transaction represents direct beneficial ownership and was filed under Section 16(a) of the Securities Exchange Act of 1934, which requires company insiders including directors to report changes in ownership of company securities.

The immediate vesting feature of these restricted stock units distinguishes this grant from typical employee equity awards that phase in over multi-year periods. Under the terms disclosed, the units vest immediately upon grant date, providing Doughtie with the economic benefits of the award without delay. However, the actual delivery of underlying common shares remains subject to deferral until Doughtie's tenure on the McKesson board concludes, a structure that maintains a continuing equity interest aligned with her service obligations.

Deferred Share Delivery Structure and Board Service

The arrangement whereby restricted stock units vest immediately but share delivery is deferred until departure from the board represents a common approach used by large corporations to retain board continuity and maintain director engagement. This structure ensures that directors retain a meaningful financial stake in company performance even as their board service continues, while the eventual share settlement occurs when the director transitions off the board. The deferral approach can help reduce immediate dilution considerations for the company while providing deferred compensation to departing directors.

McKesson's use of this compensation mechanism reflects the company's approach to director governance and retention. Deferred share delivery structures are intended to encourage ongoing board participation and sustained commitment to shareholder interests throughout a director's tenure. The immediate vesting combined with deferred settlement balances the company's desire to provide valuable equity compensation while managing the timing and settlement of share issuance.

Regulatory Filing and Insider Disclosure Requirements

The disclosure of Doughtie's restricted stock unit grant was filed on July 23, 2026, one day after the transaction date of July 22, 2026. This timing complies with Securities and Exchange Commission requirements for Form 4 filings, which mandate that directors and officers report changes in beneficial ownership within two business days of the transaction. The report was signed by Sarah Ahmad Ali, identified as attorney-in-fact for the reporting person, indicating that the filing was executed on behalf of Doughtie in accordance with appropriate authorization.

Insider trading reports such as this one provide transparency to investors regarding changes in company stock ownership by those with access to material nonpublic information. The 277 restricted stock units represent Doughtie's newly acquired beneficial ownership position in McKesson common stock, to be held in direct form upon eventual settlement. Such disclosures allow investors to monitor director and insider transactions as one factor in assessing management and board confidence in the company's strategic direction and financial prospects.

McKesson's Business Model and Director-Level Governance

As one of the largest healthcare companies globally, McKesson operates across pharmaceutical distribution, specialty healthcare services, medical-surgical products distribution, and healthcare technology platforms. The company's board of directors provides oversight of strategy, risk management, and executive performance across these diverse operating segments. Director compensation, including equity awards like the restricted stock units granted to Doughtie, reflects the complexity and scope of governance responsibilities at a multinational healthcare enterprise.

Board service at McKesson requires directors to evaluate strategic initiatives in pharmaceutical supply chain management, healthcare information technology development, specialty pharmaceutical logistics, and emerging healthcare delivery models. The equity compensation provided to directors aligns their long-term financial interests with shareholder returns, encouraging rigorous oversight of management decisions affecting shareholder value. Doughtie's board position contributes to governance oversight across McKesson's operating divisions and corporate strategy.

Comparative Context for Director Equity Awards

Director compensation practices at Fortune 500 healthcare and logistics companies typically combine annual cash retainers ranging from $100,000 to $250,000, meeting attendance fees, committee leadership premiums, and equity awards valued between $150,000 and $250,000 annually. The restricted stock unit grant to Doughtie represents one component of her total board compensation package. The immediate vesting structure with deferred settlement is less common than time-based or performance-based vesting schedules but serves specific corporate governance objectives related to director continuity.

The number of shares underlying restricted stock units granted to directors often varies based on equity award values, stock price at grant date, and individual board member responsibilities. Director equity awards are monitored by investors and governance analysts as indicators of compensation competitiveness and alignment with peer company practices. McKesson's approach to director equity compensation reflects its position as a large-capitalization healthcare company competing for experienced board leadership in the pharmaceutical distribution and healthcare technology sectors.

McKesson's Stock Plan Framework and Equity Administration

The 2022 Stock Plan under which Doughtie's restricted stock units were granted serves as McKesson's primary vehicle for equity compensation across employee, executive, and director populations. Such stock plans typically authorize issuance of awards up to specified share limits approved by shareholders, with separate allocations for different beneficiary classes. The plan is administered by the compensation committee of McKesson's board, which determines award levels, vesting schedules, and participation criteria.

Restricted stock units represent a flexible equity award vehicle that has become standard practice at publicly traded companies seeking to provide equity compensation without requiring immediate cash investment from grantees. The units represent the right to receive underlying shares upon satisfaction of specified conditions, typically involving the passage of time and continued employment or service. The administrative simplicity and tax efficiency of restricted stock units compared to stock options or restricted shares have made them the predominant form of equity compensation in modern corporate practice.

Director Beneficial Ownership Position Following Grant

Following the restricted stock unit grant, Doughtie's beneficial ownership position in McKesson common stock reflects the 277 units granted on July 22, 2026. Beneficial ownership encompasses both direct ownership and indirect interests in company securities. The disclosure form indicates this was recorded as direct beneficial ownership, meaning the units are owned directly by Doughtie rather than through trusts, family entities, or other intermediary structures.

Beneficial ownership reporting provides investors with insight into the aggregate stock holdings of company insiders and directors. The cumulative beneficial ownership position of board members can reflect confidence in company strategy and valuation. As additional equity awards are granted or transactions occur, these beneficial ownership positions are updated in subsequent insider trading reports, allowing investors to track changing insider investment levels.

Timeline and Filing Compliance

The transaction occurred on July 22, 2026, with the regulatory report filed on July 23, 2026, maintaining compliance with the two-business-day reporting window established by Securities and Exchange Commission rules. The grant was characterized as an acquisition of securities under the transaction code applicable to acquisitions of non-derivative securities. The reporting date of July 23, 2026 represents the date the disclosure was submitted to the Commission and became publicly available information.

Timely filing of insider transaction reports ensures that investors have prompt access to information about changes in company insider holdings. The Securities and Exchange Commission maintains a public database of all Form 4 filings, allowing investors to search and review insider transactions by company, individual, and transaction type. This public transparency mechanism supports informed investor decision-making regarding insider confidence and alignment with shareholder interests.